Last Updated: November 8, 2026

Details for Patent: 7,153,964

« Back to Dashboard


Summary for Patent: 7,153,964
Title:Pyrimidine compounds
Abstract:Pyrimidine derivatives of formula (I) wherein: Qh1 and Q2 are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one of Q1 and Q2 or both Q1 and Q2 is substituted on a ring carbon by one group selected from sulphamoyl, N—(C1-4alkyl)sulphamoyl (optionally substituted by halo or hydroxy), N,N-di-(C1-4alkyl)sulphamoyl (optionally substituted by halo or hydroxy), C1-4alkylsulphonyl (optionally substituted by halo or hydroxy) or a substituent of the formula (Ia) or (Ia′): wherein Q1, Q2, G, R1, Y, Z, Q3, n and m are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) inhibitors are also described
Inventor(s):Elizabeth Janet Pease, Gloria Anne Breault, Jeffrey James Morris
Assignee: AstraZeneca AB
Application Number:US10/220,139
Patent Claim Types:
see list of patent claims
Composition; Compound; Process;

Drugs Protected by US Patent 7,153,964

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,153,964

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004888.4Mar 1, 2000
PCT Information
PCT FiledFebruary 26, 2001PCT Application Number:PCT/GB01/00782
PCT Publication Date:September 07, 2001PCT Publication Number: WO01/64654

International Family Members for US Patent 7,153,964

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1272477 ⤷  Start Trial 92824 Luxembourg ⤷  Start Trial
European Patent Office 1272477 ⤷  Start Trial CA 2015 00050 Denmark ⤷  Start Trial
European Patent Office 1272477 ⤷  Start Trial 1590048-3 Sweden ⤷  Start Trial
European Patent Office 1272477 ⤷  Start Trial 15C0064 France ⤷  Start Trial
European Patent Office 1272477 ⤷  Start Trial CR 2015 00050 Denmark ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.